Luitpold hoping for third time lucky as Injectafer resubmitted in US
This article was originally published in Scrip
More than three years after the US FDA issued a second non-approvable letter for the product over safety concerns, Daiichi Sankyo's US subsidiary Luitpold Pharmaceuticals has resubmitted an NDA for its intravenously injected iron preparation Injectafer (ferric carboxymaltose).
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.